Results Of Nanoform Collaborative Study To Be Presented At U.S. Drug Delivery & Formulation (DDF) Summit
Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), a leading nanoparticle medicine performance-enhancing company, today announced that key findings from two studies conducted in collaboration between Nanoform and Takeda will be presented at the 15th American Drug Delivery & Formulation Summit (DDF) in Boston, Mass., on September 16, 2025, at 09:10 – 09:40 in Room 1.
The presentation entitled “Delivering Value for Patients Through Nanoforming in Plasma-Derived Therapies” will focus on two proof-of-concept studies conducted using Nanoform technology to enhance subcutaneous and inhaled biologic treatments.
The first study evaluated the suitability of nanoformed high-concentration biologics formulations for subcutaneous delivery. Protein concentrations above 200 mg/mL often exceed the acceptable viscosity limit for subcutaneous injection. The findings, supported by syringeability studies suggest that Nanoform’s patented biologics platform can achieve high protein concentrations in suspension formulations suitable for subcutaneous delivery.
The second non-clinical proof-of-concept study investigated nanoformed Alpha-1 antitrypsin (A1AT) in the treatment of Alpha-1 antitrypsin (AAT) deficiency, a genetic disorder linked to lung diseases such as emphysema. Results showed that the nanoformed therapy showed promise as a targeted therapeutic approach. AAT deficiency is typically treated with weekly IV infusions of plasma-derived AAT, which is often inconvenient for patients. The study evaluated dry powder inhalation as an alternative route of administration for AAT replacement therapy, leveraging Nanoform’s novel solidification platform.
The 15th American Drug Delivery & Formulation Summit runs from September 15-16, 2025 (American Drug Delivery & Formulation Summit 2025) at The Westin Copley Place, Boston, Mass.
Nanoform also announced that Dr. Christopher P. Worrall, Ph.D., Vice President of Business Development, US, Nanoform, will present key case-study findings during a Solution Spotlight session at DDF.
His presentation, titled “Highly Concentrated mAb SubQ Formulations Using Nanoformed Particles: Trastuzumab,” will take place in Room 1 on Monday, September 15, from 12:15 to 12:45 p.m. EST, and will highlight the development of a highly concentrated, non-aqueous subcutaneous formulation of trastuzumab developed using Nanoform’s Bio platform.
For more information on the summit visit: nanoform.com/events. To arrange a meeting with Dr. Worrall at the DDF event, contact Christian Jones, Chief Commercial Officer, Nanoform, christian.jones@nanoform.com.
For further information, please contact:
Christian Jones, Chief Commercial Officer
Christian.jones@nanoform.com
+44 (0)7804 474 771
Henri von Haartman, Director of Investor Relations
hvh@nanoform.com
+46 (0)7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 8 588 685 70, certifiedadviser@carnegie.se. For more information, please visit www.nanoform.com.
Source: Nanoform